* If you want to update the article please login/register
Paraatoma lecticularia, a regional triatomine bug vector of T. cruzi, has undergone a genus-level reclassification. T. cruzi genetics and blood meal analyses have shown promise as a way to study complex ecological cycles. The lack of documented human Chagas disease cases in the region have been investigated, with 94. 8% of confirmed human Chagas disease infections in imported exotic animals in Mississippi found, and the lack of consistent human Chagas disease data in the area has been investigated. In addition, an ecological framework for the kissing bug Triatoma sanguisuga as a nidicolous insect is suggested. Summary T. cruzi and its insect vectors in the southeastern United States' latest research has furthered the knowledge of this unique vector-borne disease path in the region.
Source link: https://doi.org/10.1007/s40475-022-00260-x
We make recommendations for increasing access to Chagas disease diagnosis and care in the United States by showcasing screening services for Chagas disease that currently exist in endemic and non-endemic settings. Outlined are several examples of successful screening services for Chagas disease in other countries as well as in certain areas of the United States, including those that focus on high-risk populations and connecting to affordable and effective treatment options. Summary Given that Chagas disease prevalence and even risk of transmission in the United States is likely to rise in the United States, there is a need for improving detection and treatment of the disease. We recommend integrating Chagas disease into relevant clinical guidelines, especially in cardiology and obstetrics/gynecology, and advocating advocacy as a way to raise Chagas disease.
Source link: https://doi.org/10.1007/s40475-022-00264-7
We've found the prodrug AN15368, which is activated by parasite carboxypeptidases, as well as the excellent models for rapid drug screening and optimization in T. cruzi, which is based on ongoing drug discovery studies in T. cruzi. AN15368 was found to be infectious in vitro and in vivo against a variety of genetically distinct T. cruzi lineages, and was uniformly curative in non-human primates with long-term naturally acquired infections.
Source link: https://doi.org/10.1038/s41564-022-01211-y
Based on findings from the phase 3 CHICO study, the antiparasitic drug nifurtimox was approved in the United States in 2020 for the treatment of patients with Chagas disease aged less than 18 years and weighing at least 2. 5 kg. Pediatric patients with Chagas disease take nifurtimox thrice daily with food at one of two body weight ranges, according to the u2013 adjusted dose ranges. To determine nifurtimox exposure at the patient level, we investigated potential correlations between pharmacokinetic data, pharmacokinetic efficacy, and safety data obtained in an analysis sample of 111 individuals in CHICO using a published population PK model to estimate nifurtimox exposure at the patient level. Pediatric exposure to nifurtimox was compared against levels of nifurtimox exposure that was known to be safe in adults with Chagas disease in adults. We also simulated nifurtimox exposure associated with simpler dosing methods given the difficult dosing regimen for nifurtimox.
Source link: https://doi.org/10.1208/s12248-022-00742-w
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions